Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment

NCT00221650 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT00221650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00221650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2002
Completion date
June 30, 2004
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic, hiv infections, treatment failure